The well-known diuretic Ethacrynic acid (EA, Edecrin), showing low anti-proliferative activities, was chemically modified at different positions. The new EA derivatives have been tested in vitro in anti-proliferative assays on both tumor KB (epidermal carcinoma) and leukemia HL60 (promyelocytic) cells suitable targets for anticancer activity. Reduction of the α-β double bond of EA completely abolished anti-cancer activities, whereas introduction of either 2-(4-substituted phenyl)ethanamine (series A) or 4-(4-substituted phenyl)piperazine (series B) moieties generated compounds showing moderate to strong anti-proliferative activities against human cancer cell lines. Several substitutions on the phenyl of these two moieties are tolerated. The mechanism of action of the EA derivatives prepared in this study is more complex than the inhibition of glutathione S-transferase π ascribed as unique effect to EA and might help to overcome tumor resistances.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejmech.2016.05.063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the GSTP1 inhibition potential of photosensitizer compounds for enhanced cancer treatment in photodynamic therapy.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Medical Biochemistry, Faculty of Medicine, Mugla Sitki Kocman University, Mugla, Turkey.
Photodynamic therapy (PDT) has gained considerable attention in cancer treatment due to its non-invasive nature and the ability of photosensitizers to generate reactive oxygen species upon light activation, leading to tumor destruction. Glutathione S-transferase P1 (GSTP1) is a key enzyme in chemotherapy resistance, often overexpressed in various cancers, and its inhibition of GSTP1 presents a promising strategy to enhance cancer treatment. This study is aimed at assessing the potential of prominent photosensitizers as GSTP1 inhibitors through molecular docking analysis to strengthen the efficacy of PDT.
View Article and Find Full Text PDFPositively-charged, chalcone-hydroxypyrone hybrid ruthenium(II)-arene complexes functionalized with ethacrynic acid: Synthesis, characterizaion, and antitumor effect.
J Inorg Biochem
February 2025
Key Laboratory of Chemical Biology of Hebei Province; Key Laboratory of Medicinal Chemistry and Molecular Diagnosis of Ministry of Education; State Key Laboratory of New Pharmaceutical Preparations and Excipients, College of Chemistry & Materials Science, Hebei University, Baoding 071002, China. Electronic address:
A new family of ethacrynic acid-functionalized, chalcone-hydroxypyrone hybrid ruthenium(II)-arene complexes (4a-4e) have been designed, synthesis and fully characterized by H and C NMR, ESI-MS, elemental analysis, and melting point tests. The molecular structure of 3a, one of the precursor complexes, has been determined by single-crystal X-ray diffraction. The cytotoxicity of the obtained complexes toward human cancer cell lines such as HeLa, MGC803, A549, MDA-MB-231, and MCF-7 cells have been investigated by MTT assay.
View Article and Find Full Text PDFIdentification of BocLys-Linked Ethacrynic Acid and Its Analogues As Efficient Glutathione S-Transferase Degraders.
ACS Med Chem Lett
November 2024
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China.
Targeted protein degradation has been emerging as a promising strategy for drug design and a useful tool for the research of intracellular protein function by specifically downregulating the protein level via promoted degradation. Aside from proteolysis targeting chimeras (PROTAC) that utilize a specific E3 ligase ligand as a tag to recruit polyubiquitin onto the targeted protein and subsequently induce degradation, BocArg was also reported an efficient tag to induce degradation through directly localizing the protein to the 20S proteasome. Based on the similarity of BocLys and BocArg, we identified that BocLys also efficiently induced targeted protein degradation, taking glutathione S-transferase as an example.
View Article and Find Full Text PDFPreparation of Glutathione-Regulated Sorafenib Targeted Nanodrug Delivery System and Its Antihepatocellular Carcinoma Activity.
ACS Appl Mater Interfaces
November 2024
Institute of Microbial Engineering, Laboratory of Bioresource and Applied Microbiology, School of Life Sciences, Henan University, Kaifeng 475004, Henan, China.
Article Synopsis
- Researchers created a targeted nanodrug delivery system, called SMEH nanoparticles, to improve the effectiveness of sorafenib (SOR) for liver cancer treatment by reducing glutathione (GSH) levels in tumor cells.
- The preparation involved synthesizing mesoporous silica nanoparticles, modifying them, loading them with SOR, and coating them with hyaluronic acid, allowing targeted entry into tumor cells.
- Experimental results show that SMEH nanoparticles successfully target liver cancer cells, lower GSH levels, enhance antitumor effects, and demonstrate good safety, indicating their potential for cancer therapy.
Improved intracochlear biopolymeric drug delivery system: an study.
Acta Otolaryngol
December 2024
Department of Otolaryngology - Head and Neck Surgery, University of Miami Ear Institute, University of Miami, Miller School of Medicine, Miami, FL, USA.
Background: The delivery of drugs into the inner ear is a challenging field of study due to the complex cochlear anatomy and physiology. The creation of an intracochlear device that allows for short- and long-term intracochlear delivery of the drugs with a minimal invasive technology is needed to prevent or treat conditions that can potentially prevent the development of permanent hearing loss.
Aim: This study intends to test the efficacy of DXM-infused PLGA microneedles created in our laboratory in an animal model of acute ototoxic injury.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!